Three startups with funding from major technologies companies are working to receive FDA approval on blood tests that screen for cancer, according to CNBC.
Freenome, a startup with backing from Alphabet's Verily, has developed a blood test that detects two major biomarkers in patients' blood in order to help identify early stage colorectal cancer. Additionally, the blood test is designed to find tiny fragments of DNA from a tumor in patients' bloodstream.
With support from Amazon, Grail is developing blood tests that can identify multiple types of cancers.
Similar to Grail, startup Thrive wants to commercialize a blood test developed by researchers at Baltimore-based Johns Hopkins that detects cancer. Thrive's blood test currently can identify pancreatic and ovarian cancers. The company recently secured financing from former Google Ventures chief Bill Maris.
To read more, click here.